Serum carboxypeptidase activity and genotype-stratified CA19-9 to detect early-stage pancreatic cancer

Serum diagnostic markers of early-stage pancreatic ductal adenocarcinoma (PDAC) are needed, especially for Stage I disease. As tumors grow and cause pancreatic atrophy, markers derived from pancreatic parenchyma such as serum carboxypeptidase A activity (CPA) lose diagnostic performance. We evaluated, with CA19-9, serum CPA as a marker of early pancreatic cancer.

Source: Clinical Gastroenterology and Hepatology - October 11, 2021 Category: Gastroenterology Authors: Haruyoshi Tanaka, Koji Tamura, Toshiya Abe, Takeichi Yoshida, Anne Macgregor-Das, Mohamad Dbouk, Amanda L. Blackford, Michael Borges, Anne Marie Lennon, Jin He, Richard Burkhart, Marcia Irene Canto, Michael Goggins Source Type: research